Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Sphincter Preservation Surgery and Abdominoperineal Resection (APR): Prospective Clinical Trial (ASPIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01461525
Recruitment Status : Active, not recruiting
First Posted : October 28, 2011
Last Update Posted : October 8, 2019
Sponsor:
Collaborators:
Seoul National University Bundang Hospital
National Cancer Center, Korea
Seoul National University Boramae Hospital
Hallym University Medical Center
Daehang Hospital
Information provided by (Responsible Party):
Sung-Bum Kang, Seoul National University Bundang Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Sphincter preservation surgery in low rectal cancer has been increased due to better understanding of tumor biology and advances in surgical technology. Furthermore, a majority of patients prefer sphincter preservation rather than living with permanent colostomy. But it is not clear whether sphincter preservation is directly related with better quality of life. There have been many studies comparing sphincter preservation surgery and abdominoperineal resection in many aspects including oncologic and functional outcomes, and the quality of life. However, the conclusion remains controversial because of the different results between studies.

Condition or disease Intervention/treatment Phase
Rectal Cancer Procedure: Abdominoperineal resection Procedure: Sphincter preservation surgery Not Applicable

Detailed Description:
This prospective study was designed to compare the quality of life after sphincter saving surgery and abdominoperineal resection. Because of ethical issues, it is difficult to conduct as a randomized trial. On the basis of tumor location, extent, and preoperative anal function, patient will be attributed to two different operative method groups. On the assumption that 10% of the patients are lost to follow-up at 1 year, at least 74 patients undergoing APR and 220 patients undergoing SPS will be recruited. The study will be continued until the target sample size will be achieved.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 342 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Sphincter Preservation Surgery Versus Abdominoperineal Resection for Low Rectal Cancer: Prospective Clinical Trial
Study Start Date : October 2011
Actual Primary Completion Date : September 2019
Estimated Study Completion Date : September 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Sphincter preservation surgery
Temporary ileostomy with anal sphincter preservation
 Procedure: Sphincter preservation surgery
After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
Other Name: SPS
Experimental: Abdominoperineal Resection
Permanent colostomy with total anal sphincter sacrifice
 Procedure: Abdominoperineal resection
After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
Other Names:
  • APR
  • Miles' operation


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Quality of life outcome [ Time Frame: 3 years ]
    Measured by EORTC-QLQ C30, CR38 questionnaires at preoperative(baseline)and postoperative(12,24,36 months).


Secondary Outcome Measures :
  1. Oncologic outcomes [ Time Frame: 5 years ]
    Oncologic outcomes (recurrence, survival)

  2. Bladder function [ Time Frame: 3 years ]
    Measured by IPSS questionnaire at preoperative(baseline)and postoperative(12,24,36 months).

  3. Sexual function [ Time Frame: 3 years ]
    Measured by FSFI,IIEF-5 questionnaires at preoperative(baseline)and postoperative(12,24,36 months).

  4. Anal function [ Time Frame: 3 years ]
    Only patients with sphincter preservation surgery, measured by manometry and MSKCC questionnaire at preoperative(baseline)and after ileostomy repair (12,24,36 months).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Low rectal cancer (5cm from anal verge by surgeon's digital rectal exam / rigid rectoscopy)
  • Patient who understands and accepts to sign the informed consent form
  • Confirmed preoperative colonoscopic biopsy (adenocarcinoma)
  • Proper bone marrow function
  • Proper renal function
  • Proper liver function
  • No severe comorbidity

Exclusion Criteria:

  • Metastatic lesion detected in preoperative assessment
  • Previous history of cancer disease. (except patients with skin cancer)
  • Severe heart disease, congestive heart disease.
  • Severe lung disease, respiratory failure.
  • Mental illness.
  • Invasion to prostate, bladder and combined resection needed (partial or radical.• Legally prohibited for clinical trial.
  • Pregnancy or breast feeding.
  • Previous disease or disability expected to influence the assessment of postoperative quality of life.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01461525


Locations
Layout table for location information
Korea, Republic of
Hallym University College of Medicine
Anyang, Gyeong-gi, Korea, Republic of, 431-070
National Cancer Center
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
Seoul National University Bundang Hospital
SeongNam, GyeongGi, Korea, Republic of, 463-707
Seoul National University Hospital
Seoul, Jongno-gu, Korea, Republic of, 110-744
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, Korea, Republic of, 156-707
Daehang Hospital
Seoul, Korea, Republic of, 481-10
Sponsors and Collaborators
Seoul National University Hospital
Seoul National University Bundang Hospital
National Cancer Center, Korea
Seoul National University Boramae Hospital
Hallym University Medical Center
Daehang Hospital
Investigators
Layout table for investigator information
Principal Investigator: Sung-Bum Kang, Ph. D. Seoul National University Bundang Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sung-Bum Kang, Director of Colorectal Cancer Center, Principal Investigator, Professor, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT01461525    
Other Study ID Numbers: APR-SPS trial
First Posted: October 28, 2011    Key Record Dates
Last Update Posted: October 8, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Sung-Bum Kang, Seoul National University Bundang Hospital:
Low Rectal Cancer
Sphincter preservation
Abdominoperineal resection
Quality of life
 Sexual function
Urinary function
Oncologic outcome
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
 Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases